Project Grant R44EY036343
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$1.1M
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38120, USA
Similar Awards
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis in glaucoma through senolytic treatments. The $234,000 award to Oregon Health & Science University aims to use senolytics and senoreverters to restore TM cell IOP homeostatic function in glaucomatous tissue, with or without stem cell transplantation. This research has the...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
The National Eye Institute (NEI), through its Vision Research federal grant program (CFDA 93.867), awarded a $679,159 Project Grant to The Schepens Eye Research Institute, Inc. in Boston, Massachusetts. The grant, awarded on May 1, 2025, supports research aimed at understanding how aging and elevated intraocular pressure (IOP) contribute to the development of glaucoma and impact retinal ganglion cells (RGCs). The research project will investigate the transcriptomic changes in RGCs due to aging...
This Project Grant award, valued at $728,165 and provided by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867), supports research into the role of orexins in regulating intraocular pressure (IOP) as it relates to glaucoma. The key objectives are to: Examine the role of the brainstem raphe pallidus region in mediating DMH/PEF-induced IOP elevations by measuring the impact of local orexin receptor antagonists. Assess the degree to which orexin...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to define the role of the RIG-I protein in the pathogenesis of glaucoma and the response to viral infections. The $603,251 award, effective from July 1, 2025 to April 30, 2030, will support the following key activities: Elucidating the molecular mechanisms by which RIG-I variants cause glaucoma in a mouse model through genetic perturbation, histological, and single-cell...
This federal Project Grant awarded by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), aims to develop a safe and effective topically administered pharmacotherapy to treat acute corneal pain. The $590,172 award to Vyluma Inc., with a period of performance from Sep 30, 2024 to Aug 31, 2025, will support three specific research aims: 1) a pharmacodynamic dose identification study to determine the minimum effective dose of the pregabalin-based...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The $257,785 award to The Leland Stanford Junior University (Stanford University) will support research to characterize and control the release of adalimumab and a novel...
This Project Grant award of $1,593,473.00, provided by the National Eye Institute under the Vision Research program (CFDA 93.867), will support a multiomic analysis of preclinical biomarkers for primary open-angle glaucoma (POAG). The study aims to analyze proteomic and metabolomic markers, and their interactions with genetic predisposition, to advance understanding of POAG pathophysiology. Researchers will use plasma samples from a nested case-control group within ongoing prospective cohorts,...